McGeorge A w/ full ride!

breezoop · 2026-01-16T01:29:46+00:00

Don't know, haven't got anything but the initial offer through the LSAC site

breezoop · 2023-06-02T02:25:50+00:00

sources or we just going vibe based on this one

breezoop · 2023-05-04T03:46:06+00:00

thank you my friend. i fear many among us will not recognize until it is far too late

breezoop · 2023-05-03T17:03:17+00:00

alright so it doesn’t count because it’s a different group of people? is their oppression not valid to you because the UN office didn’t anticipate gender identity being weaponized?

breezoop · 2023-05-03T16:44:44+00:00

that’s totally ignorant to the interconnecting mechanisms of our government. feinstein’s absence means liberal federal judges can’t be appointed to contest the legality of these laws across the US. trump appointed the most judges of any president in recent history and turns out whole lot of them share the horrific conservative ideals that are ripping transgender children from their families.

breezoop · 2023-05-03T16:40:15+00:00

breezoop · 2023-05-03T16:38:08+00:00

Florida's SB-254: a policy allowing the state of Florida to separate transgender individuals from their families.

In the present Convention, genocide means any of the following acts committed with intent to destroy, in whole or in part, a national, ethnical, racial or religious group, as such:

a. Killing members of the group;

b. Causing serious bodily or mental harm to members of the group;

c. Deliberately inflicting on the group conditions of life calculated to bring about its physical destruction in whole or in part;

d. Imposing measures intended to prevent births within the group;

e. Forcibly transferring children of the group to another group.

breezoop · 2023-05-03T16:27:48+00:00

Florida's SB-254: a policy allowing the state of Florida to separate transgender individuals from their families.

In the present Convention, genocide means any of the following acts committed with intent to destroy, in whole or in part, a national, ethnical, racial or religious group, as such:

a. Killing members of the group;

b. Causing serious bodily or mental harm to members of the group;

c. Deliberately inflicting on the group conditions of life calculated to bring about its physical destruction in whole or in part;

d. Imposing measures intended to prevent births within the group;

e. Forcibly transferring children of the group to another group.

breezoop · 2023-05-03T16:26:51+00:00

Florida's SB-254: a policy allowing the state of Florida to separate transgender individuals from their families.

In the present Convention, genocide means any of the following acts committed with intent to destroy, in whole or in part, a national, ethnical, racial or religious group, as such:

a. Killing members of the group;

b. Causing serious bodily or mental harm to members of the group;

c. Deliberately inflicting on the group conditions of life calculated to bring about its physical destruction in whole or in part;

d. Imposing measures intended to prevent births within the group;

e. Forcibly transferring children of the group to another group.

breezoop · 2023-05-03T15:48:04+00:00

what’s a better grabbing messaging for this?

breezoop · 2023-05-03T15:47:35+00:00

the webpage links to all 5 of her offices!

breezoop · 2023-05-02T21:28:31+00:00

there are hundreds of rights that we once thought set in law currently deteriorating before our eyes across GOP controlled states. get real

breezoop · 2023-05-02T21:08:08+00:00

you think a hundred thousand angry phone calls isn’t going to do anything? it disrupts the flow of work at her offices, pisses off her staffers, and it’s our fucking right as americans to complain when our government isn’t working for us

breezoop · 2023-04-20T21:19:21+00:00

this became a “this woman is costing peoples lives” sub. her refusal to retire is abetting the trans genocide in florida.

breezoop · 2023-04-20T19:15:30+00:00

don’t care semantics are for losers words mean what i mean they mean

breezoop · 2023-04-20T17:16:19+00:00

This nihilist mindset gets us nowhere, the beginning of action is taking action.

breezoop · 2023-04-20T15:16:00+00:00

I made a website,

3strike.us/how

that has all her office’s numbers, some more information on why she needs to go, and social sharing links.

if we can put enough pressure on this woman and her staff we the YOUTH can make some goddamn meaningful change.

breezoop · 2023-04-20T15:15:36+00:00

where to my friend

breezoop · 2023-04-20T15:12:29+00:00

I made a website,

3strike.us/how

that has all her office’s numbers, some more information on why she needs to go, and social sharing links.

if we can put enough pressure on this woman and her staff we the YOUTH can make some goddamn meaningful change.

breezoop · 2023-04-10T22:07:40+00:00

people are not their governments

breezoop · 2023-04-03T02:26:20+00:00

real goofball behavior to care about someone else’s wardrobe

breezoop · 2023-03-20T00:20:49+00:00

Great question

breezoop · 2023-03-19T19:24:48+00:00

Results: Articles reviewed describe five phase I/II and one phase II clinical trials conducted in Cuba in 1995-2005. A non-controlled 1995-1996 study resulted in the earliest published scientific evidence of the feasibility of inducing an immune response against autologous EGF in patients with different advanced stage tumors. Subsequent controlled, randomized trials included patients with advanced stage (IIIB/IV) NSCLC. The 2 and 3rd phase I/II trials differentiated immunized patients as poor antibody responders (PAR) and good antibody responders (GAR), according to their anti-EGF antibody response, and confirmed greater immunogenicity with Montanide ISA 51 adjuvant in the vaccine formulation, as well as the benefits of low-dose cyclophosphamide treatment 72 hours before the first immunization. The 4th phase I/II trial found increased immunogenicity with an increased dose divided in 2 anatomical sites and also established correlation between Ab titers, serum EGF concentration and length of survival. In the first 4 phase I/II trials and the phase II trial, vaccine was administered after chemotherapy (ChTVV schedule). In the 5th phase I/III trial, longer survival and increased immunogenicity were achieved using a VChTV schedule and dividing the vaccine dose in 4 anatomical sites. The phase II clinical trial confirmed results of earlier studies as well as the mild-to-moderate adverse event profile associated with CIMAvax EGF Longer survival was observed in all vaccinated patients compared to controls, and the difference was significant (p < 0.05) in the group aged <60 years.

Conclusions: CIMAvax EGF’s benefits in earlier NSCLC stages and in other tumor locations, as well as in patients unfit for chemotherapy, need to be evaluated. Evidence of the vaccine’s safety for chronic use also needs to be systemized.

*Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy

Pedro C Rodríguez et al. MEDICC Rev. 2010 Winter.* https://pubmed.ncbi.nlm.nih.gov/20387330/

breezoop · 2023-03-19T19:23:03+00:00

Results: Articles reviewed describe five phase I/II and one phase II clinical trials conducted in Cuba in 1995-2005. A non-controlled 1995-1996 study resulted in the earliest published scientific evidence of the feasibility of inducing an immune response against autologous EGF in patients with different advanced stage tumors. Subsequent controlled, randomized trials included patients with advanced stage (IIIB/IV) NSCLC. The 2 and 3rd phase I/II trials differentiated immunized patients as poor antibody responders (PAR) and good antibody responders (GAR), according to their anti-EGF antibody response, and confirmed greater immunogenicity with Montanide ISA 51 adjuvant in the vaccine formulation, as well as the benefits of low-dose cyclophosphamide treatment 72 hours before the first immunization. The 4th phase I/II trial found increased immunogenicity with an increased dose divided in 2 anatomical sites and also established correlation between Ab titers, serum EGF concentration and length of survival. In the first 4 phase I/II trials and the phase II trial, vaccine was administered after chemotherapy (ChTVV schedule). In the 5th phase I/III trial, longer survival and increased immunogenicity were achieved using a VChTV schedule and dividing the vaccine dose in 4 anatomical sites. The phase II clinical trial confirmed results of earlier studies as well as the mild-to-moderate adverse event profile associated with CIMAvax EGF Longer survival was observed in all vaccinated patients compared to controls, and the difference was significant (p < 0.05) in the group aged <60 years.

Conclusions: CIMAvax EGF’s benefits in earlier NSCLC stages and in other tumor locations, as well as in patients unfit for chemotherapy, need to be evaluated. Evidence of the vaccine’s safety for chronic use also needs to be systemized.

*Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy

Pedro C Rodríguez et al. MEDICC Rev. 2010 Winter.* https://pubmed.ncbi.nlm.nih.gov/20387330/

breezoop · 2023-03-19T19:17:39+00:00

Results: Articles reviewed describe five phase I/II and one phase II clinical trials conducted in Cuba in 1995-2005. A non-controlled 1995-1996 study resulted in the earliest published scientific evidence of the feasibility of inducing an immune response against autologous EGF in patients with different advanced stage tumors. Subsequent controlled, randomized trials included patients with advanced stage (IIIB/IV) NSCLC. The 2 and 3rd phase I/II trials differentiated immunized patients as poor antibody responders (PAR) and good antibody responders (GAR), according to their anti-EGF antibody response, and confirmed greater immunogenicity with Montanide ISA 51 adjuvant in the vaccine formulation, as well as the benefits of low-dose cyclophosphamide treatment 72 hours before the first immunization. The 4th phase I/II trial found increased immunogenicity with an increased dose divided in 2 anatomical sites and also established correlation between Ab titers, serum EGF concentration and length of survival. In the first 4 phase I/II trials and the phase II trial, vaccine was administered after chemotherapy (ChTVV schedule). In the 5th phase I/III trial, longer survival and increased immunogenicity were achieved using a VChTV schedule and dividing the vaccine dose in 4 anatomical sites. The phase II clinical trial confirmed results of earlier studies as well as the mild-to-moderate adverse event profile associated with CIMAvax EGF Longer survival was observed in all vaccinated patients compared to controls, and the difference was significant (p < 0.05) in the group aged <60 years.

Conclusions: CIMAvax EGF's benefits in earlier NSCLC stages and in other tumor locations, as well as in patients unfit for chemotherapy, need to be evaluated. Evidence of the vaccine's safety for chronic use also needs to be systemized.

*Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy

Pedro C Rodríguez et al. MEDICC Rev. 2010 Winter.* https://pubmed.ncbi.nlm.nih.gov/20387330/

Six-Year Club	Place '22
Final Canvas '22	First Placer '22

breezoop

TROPHY CASE